ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny
ASCO is always an interesting show for Kite, the Gilead Sciences subsidiary focused on cell therapy. At last year's ASCO23, pharmaphorum caught up with Kite’s head of commercial affairs, Warner Biddle, and this year editor-in-chief Jonah Comstock was able to speak to the company's head of medical affairs, Dr Ibrahim Elhoussieny, as well.
In the video interview below, recorded live at ASCO 2024 in Chicago, Illinois, the two of them discuss new data from the long-term follow-up of the ZUMA-3 trial for Tecartus (brexucabtagene autoleucel), which showed 40% survival at the four-year mark. They also talk about new foundational data looking at Yescarta (axticabtagene ciloleucel) in CNS lymphoma. And we get a taste of what’s to come as KITE thinks about the next generation of CAR-Ts, exploring advances in dual targeting and faster manufacturing.
As well as the news, Biddle, Elhoussieny, and Comstock talk trends, from cell therapy infrastructure and authorised treatment centres to research trends at the conference. There’s lots to cover in this energetic on-site sit-down from ASCO, so take a look below.
